I think the GlaxoSmithKline share price could help you retire early

Invest in GlaxoSmithKline now and you could benefit from a share price recovery, driven by increased sales, profits and a generous quarterly dividend.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the turn of the year, the GlaxoSmithKline (LSE:GSK) share price has fallen nearly 10%. During the same period, the FTSE 100 has performed far worse, losing nearly 20% of its value. GSK’s resilience to the current economic challenges is no surprise to me, and I believe the share price is a bargain at its current price.

GlaxoSmithKline is a £33bn global healthcare behemoth that produces prescription medicines, vaccines and consumer healthcare products. Companies in the healthcare sector are non-cyclical as demand for their products remain high, regardless of the state of the economy. Up to the end of April, its sales had risen by 10% and underlying profits had increased by 14%. These strong fundamentals reaffirm my belief that any share price discount should be viewed as a great opportunity to invest.

Changing shape of the business

GlaxoSmithKline has plans to demerge the consumer healthcare side of the business via a joint venture with Pfizer within two years. The new business will sell healthcare staples, such as toothpaste, pain relief and cold and flu remedies. Consumer loyalty to brands such as Sensodyne and Paradol will ensure robust revenue streams and provide the business with defensive resilience to future economic challenges. The business will be similar in nature to sector rival Reckitt Benckiser, the owner of consumer healthcare brands such as Nurofen and Dettol.

Should you invest £1,000 in Tesco right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tesco made the list?

See the 6 stocks

The remaining GlaxoSmithKline business will focus on discovering, developing and selling prescription medicines and enhancing its large portfolio of available vaccines. Its business portfolio will be similar in nature to its sector rival AstraZeneca.

Increasing net debt to facilitate GlaxoSmithKline splitting into two has the potential to create investor uncertainty, which could negatively affect its share price. However, I believe any negative sentiment to the planned demerger is misguided.

It has long been muted by economic commentators that the sum of GlaxoSmithKline’s parts could be worth more than the whole. I don’t think this potential is factored into the current share price as the business is conservatively valued, with a price-to-earnings ratio of just 14.

Income champion

Since the UK went into total lockdown at the end of March, 41 companies in the FTSE 100 have either cut or deferred their dividend payments.

GlaxoSmithKline is an income investor’s dream, and is one of the few companies in the FTSE 100 that pays a quarterly dividend. Its dividend payments are sustainable and are covered nearly 1.5 times by free cashflow.

The 5% dividend yield is above the FTSE 100 average and dwarfs the sub-3% yields that shareholders of sector rivals Reckitt Benckiser and AstraZeneca receive.

Summary

I believe the long-term prospects for GlaxoSmithKline are excellent and that the current share price is undervalued. The dividend payments are sustainable, and the yields are excellent. The pending demerger should be viewed as an opportunity to enhance extra shareholder value.

I am convinced that investing in GlaxoSmithKline at the current share price and reinvesting those generous dividends has the long-term potential to make you rich and retire early.

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben Race owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

Here’s the growth forecast for Nvidia shares through to 2026!

Demand for Nvidia shares has soared as investors eye up US growth stocks. Royston Wild looks at the chipmaker's earnings…

Read more »

a couple embrace in front of their new home
Investing Articles

Down 30% in 3 months, is the Taylor Wimpey share price too cheap for me to ignore?

Taylor Wimpey’s share price has plummeted since September and the stock now yields 8%. Should our writer buy the shares…

Read more »

Investing Articles

Is the S&P 500 heading for a correction in 2025?

This writer wonders whether the blue-chip US index is ready for a stumble, with one popular S&P 500 share up…

Read more »

Investing Articles

£15,000 invested in Tesco shares at the start of 2024 is now worth…

This writer takes a look at the performance of Tesco shares since the start of last year and considers whether…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

3 passive income ideas for Stocks & Shares ISA investors to consider!

Searching for ways to make a gigantic second income? Royston Wild reveals three ways that ISA investors could build long-term…

Read more »

Investing Articles

Beaten-down FTSE 250: a chance to get rich in 2025?

FTSE 250 stocks have endured a tough few years, with these typically UK-focused businesses suffering amid broad macroeconomic challenges.

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

6.5% dividend yield! Here’s the dividend forecast for BP shares through to 2026

City analysts expect the dividend on BP shares to keep growing. But just how robust are current estimates? Royston Wild…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Dividend Shares

Avoid these 2 mistakes that investors make with dividend stocks

Our writer examines the various pitfalls that new investors typically face when considering dividend stocks for passive income. 

Read more »